| Autor: |
Innes, Carrie R., Sykes, Peter H., Harker, Dianne, Williman, Jonathan A., Van der Griend, Rachael A., Whitehead, Martin, Hibma, Merilyn, Lawton, Beverley A., Fitzgerald, Peter, Dudley, Narena M., Petrich, Simone, Faherty, Jim, Bergzoll, Cecile, Eva, Lois, Sadler, Lynn, Simcock, Bryony J. |
| Zdroj: |
Papillomavirus Research; December 2018, Vol. 6 Issue: 1 p77-82, 6p |
| Abstrakt: |
In 2008, a quadrivalent human papillomavirus (HPV) vaccine (genotypes 6, 11, 16, 18) became available in New Zealand. This study investigated whether the proportion of cervical intraepithelial neoplasia grade 2 (CIN2) lesions associated with HPV genotypes 16 and 18 changed over time in young women recruited to a prospective CIN2 observational management trial (PRINCess) between 2013 and 2016. Partial HPV genotyping (16, 18, or other high risk HPV) was undertaken on n = 392 women under 25 years (mean age 21.8, range 17–24) with biopsy-diagnosed CIN2. High risk HPV genotypes were detected in 96% of women with CIN2 lesions. Between 2013 and 2016, the proportion of women whose liquid-based cytology samples were HPV 16 or 18 positive decreased from 43% to 13%. HPV vaccination status was known for 78% of women. Between 2013 and 2016, the proportion of HPV 16/18 positivity did not significantly change in HPV-vaccinated women, but decreased from 66% to 17% in unvaccinated women. The reducing proportion of HPV 16/18-related CIN2 in our cohort of young New Zealand women may be attributable to the introduction of a national HPV vaccination program. The substantial decrease in HPV 16/18 positivity observed in unvaccinated women is likely to be due to a herd effect. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
